159 related articles for article (PubMed ID: 36119062)
1. Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.
Bougouma EC; Palacpac NMQ; Tiono AB; Nebie I; Ouédraogo A; Houard S; Yagi M; Coulibaly SA; Diarra A; Tougan T; Ouedraogo AZ; Soulama I; Arisue N; Yaro JB; D'Alessio F; Leroy O; Cousens S; Horii T; Sirima SB
Front Immunol; 2022; 13():978591. PubMed ID: 36119062
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial.
Ouédraogo A; Bougouma EC; Palacpac NMQ; Houard S; Nebie I; Sawadogo J; Berges GD; Soulama I; Diarra A; Hien D; Ouedraogo AZ; Konaté AT; Kouanda S; Myoui A; Ezoe S; Ishii KJ; Sato T; D'Alessio F; Leroy O; Tiono AB; Cousens S; Horii T; Sirima SB
Front Immunol; 2023; 14():1267372. PubMed ID: 37908361
[TBL] [Abstract][Full Text] [Related]
3.
Tiono AB; Palacpac NMQ; Bougouma EC; Nebie I; Ouédraogo A; Houard S; Arisue N; D'Alessio F; Horii T; Sirima SB
Front Immunol; 2023; 14():1119820. PubMed ID: 36993981
[TBL] [Abstract][Full Text] [Related]
4. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.
Palacpac NM; Ntege E; Yeka A; Balikagala B; Suzuki N; Shirai H; Yagi M; Ito K; Fukushima W; Hirota Y; Nsereko C; Okada T; Kanoi BN; Tetsutani K; Arisue N; Itagaki S; Tougan T; Ishii KJ; Ueda S; Egwang TG; Horii T
PLoS One; 2013; 8(5):e64073. PubMed ID: 23724021
[TBL] [Abstract][Full Text] [Related]
5. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.
Horii T; Shirai H; Jie L; Ishii KJ; Palacpac NQ; Tougan T; Hato M; Ohta N; Bobogare A; Arakaki N; Matsumoto Y; Namazue J; Ishikawa T; Ueda S; Takahashi M
Parasitol Int; 2010 Sep; 59(3):380-6. PubMed ID: 20493274
[TBL] [Abstract][Full Text] [Related]
6. First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).
Ezoe S; Palacpac NMQ; Tetsutani K; Yamamoto K; Okada K; Taira M; Nishida S; Hirata H; Ogata A; Yamada T; Yagi M; Edula JR; Oishi Y; Tougan T; Ishii KJ; Myoui A; Horii T
Vaccine; 2020 Oct; 38(46):7246-7257. PubMed ID: 33012605
[TBL] [Abstract][Full Text] [Related]
7. African-specific polymorphisms in
Arisue N; Palacpac NMQ; Ntege EH; Yeka A; Balikagala B; Kanoi BN; Bougouma EC; Tiono AB; Nebie I; Diarra A; Houard S; D'Alessio F; Leroy O; Sirima SB; Egwang TG; Horii T
Front Cell Infect Microbiol; 2022; 12():1058081. PubMed ID: 36590593
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and protection from malaria infection in BK-SE36 vaccinated volunteers in Uganda is not influenced by HLA-DRB1 alleles.
Tougan T; Ito K; Palacpac NM; Egwang TG; Horii T
Parasitol Int; 2016 Oct; 65(5 Pt A):455-8. PubMed ID: 27343834
[TBL] [Abstract][Full Text] [Related]
9. Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda.
Yagi M; Palacpac NM; Ito K; Oishi Y; Itagaki S; Balikagala B; Ntege EH; Yeka A; Kanoi BN; Katuro O; Shirai H; Fukushima W; Hirota Y; Egwang TG; Horii T
Sci Rep; 2016 Oct; 6():34363. PubMed ID: 27703240
[TBL] [Abstract][Full Text] [Related]
10. Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5-10-Year-Old Burkinabe Children Naturally Exposed to Malaria.
Nebie I; Palacpac NMQ; Bougouma EC; Diarra A; Ouédraogo A; D'Alessio F; Houard S; Tiono AB; Cousens S; Horii T; Sirima SB
Vaccines (Basel); 2024 Feb; 12(2):. PubMed ID: 38400149
[TBL] [Abstract][Full Text] [Related]
11. [Development and application of next generation SE36 malaria vaccine formulated with a novel adjuvant: approach to travelers' vaccine].
Tougan T; Ishii KJ; Horii T
Yakugaku Zasshi; 2013; 133(11):1153-7. PubMed ID: 24189556
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.
Sirima SB; Tiono AB; Ouédraogo A; Diarra A; Ouédraogo AL; Yaro JB; Ouédraogo E; Gansané A; Bougouma EC; Konaté AT; Kaboré Y; Traoré A; Chilengi R; Soulama I; Luty AJ; Druilhe P; Cousens S; Nébié I
PLoS One; 2009 Oct; 4(10):e7549. PubMed ID: 19855847
[TBL] [Abstract][Full Text] [Related]
13. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
Lusingu JP; Gesase S; Msham S; Francis F; Lemnge M; Seth M; Sembuche S; Rutta A; Minja D; Segeja MD; Bosomprah S; Cousens S; Noor R; Chilengi R; Druilhe P
Malar J; 2009 Jul; 8():163. PubMed ID: 19607731
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.
Ouédraogo A; Tiono AB; Kargougou D; Yaro JB; Ouédraogo E; Kaboré Y; Kangoye D; Bougouma EC; Gansane A; Henri N; Diarra A; Sanon S; Soulama I; Konate AT; Watson NL; Brown V; Hendriks J; Pau MG; Versteege I; Wiesken E; Sadoff J; Nebie I; Sirima SB
PLoS One; 2013; 8(11):e78679. PubMed ID: 24244339
[TBL] [Abstract][Full Text] [Related]
15. Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences.
Yagi M; Bang G; Tougan T; Palacpac NM; Arisue N; Aoshi T; Matsumoto Y; Ishii KJ; Egwang TG; Druilhe P; Horii T
PLoS One; 2014; 9(6):e98460. PubMed ID: 24886718
[TBL] [Abstract][Full Text] [Related]
16. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.
Tougan T; Aoshi T; Coban C; Katakai Y; Kai C; Yasutomi Y; Ishii KJ; Horii T
Hum Vaccin Immunother; 2013 Feb; 9(2):283-90. PubMed ID: 23291928
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
Bélard S; Issifou S; Hounkpatin AB; Schaumburg F; Ngoa UA; Esen M; Fendel R; de Salazar PM; Mürbeth RE; Milligan P; Imbault N; Imoukhuede EB; Theisen M; Jepsen S; Noor RA; Okech B; Kremsner PG; Mordmüller B
PLoS One; 2011; 6(7):e22525. PubMed ID: 21829466
[TBL] [Abstract][Full Text] [Related]
18. [Malaria vaccine].
Horii T
Nihon Rinsho; 2008 Oct; 66(10):1990-8. PubMed ID: 18939502
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
20. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.
Laurens MB; Thera MA; Coulibaly D; Ouattara A; Kone AK; Guindo AB; Traore K; Traore I; Kouriba B; Diallo DA; Diarra I; Daou M; Dolo A; Tolo Y; Sissoko MS; Niangaly A; Sissoko M; Takala-Harrison S; Lyke KE; Wu Y; Blackwelder WC; Godeaux O; Vekemans J; Dubois MC; Ballou WR; Cohen J; Dube T; Soisson L; Diggs CL; House B; Bennett JW; Lanar DE; Dutta S; Heppner DG; Plowe CV; Doumbo OK
PLoS One; 2013; 8(11):e79323. PubMed ID: 24260195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
